Overview
Phathom Q3 2025 revenue rises 25% quarter-over-quarter, beating analyst expectations
Company updates 2025 revenue guidance to $170–$175 mln, expects profitability in 2026
Cash operating expenses down 43% quarter-over-quarter, aligning with cost-saving plans
Outlook
Phathom updates 2025 revenue guidance to $170–$175 mln
Company expects operating profitability in 2026
Phathom anticipates VOQUEZNA exclusivity through May 2032
Result Drivers
VOQUEZNA PRESCRIPTIONS - 28% increase in filled VOQUEZNA prescriptions drove revenue growth, supported by strategic sales force retargeting efforts
COST SAVINGS - Significant reduction in operating expenses due to lower promotional spend and personnel costs
COMMERCIAL COVERAGE - Stable commercial coverage with over 80% of U.S. lives covered supports revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $49.50 mln | $46.99 mln (8 Analysts) |
Q3 Net Income | -$30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $20.00, about 32.4% above its October 29 closing price of $13.53
Press Release: ID:nGNXbdJTKV
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)